Skip to main content
    O

    Oramed Pharmaceuticals Inc (ORMP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.90
    +0.19 (+5.12%)

    Market Cap: $161.33M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Oramed Pharmaceuticals Inc (ORMP) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Oramed Pharmaceuticals (ORMP) to earn $4.47 per share in the fiscal year ending Dec 31, 2026. For the quarter ending Dec 31, 2026, the EPS consensus is $0.38.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    Fiscal year ending Dec 31, 2026
    $4.47
    EPS consensus
    Next report
    Mar 24, 2027
    Estimated
    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026$4.47$4.47 to $4.471

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026$0.38$0.36 to $0.393

    EPS Trend

    Over the last 60 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 93.5% from $2.31.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$4.47$2.31$2.31$2.31N/AN/A

    Frequently Asked Questions About ORMP

    What is the ORMP stock forecast?

    Consensus analyst estimates put Oramed Pharmaceuticals's EPS at $4.47 for the fiscal year ending Dec 31, 2026.

    What EPS do analysts expect from ORMP next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $4.47, with estimates from $4.47 to $4.47 from 1 analyst.

    How many analysts cover ORMP?

    1 analyst estimates EPS for Oramed Pharmaceuticals for the fiscal year ending Dec 31, 2026.